Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome (II) + 5-FU/LV + Bevacizumab in Advanced CRC
NCT07123441Phase 2Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome injection in colorectal cancer (CRC). Primary endpoint: Incidence of Adverse Events at 3 years. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07123441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123441.